RAFAEL HOLDINGS, INC. Payments to Acquire Held-to-maturity Securities
RAFAEL HOLDINGS, INC. (RFL) reported Payments to Acquire Held-to-maturity Securities of $16.99 million for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2026-06-11
- RAFAEL HOLDINGS, INC. payments to acquire held-to-maturity securities for the quarter ending 2025-07-31 was $94.00K, a 99.57% decline year-over-year.
- RAFAEL HOLDINGS, INC. payments to acquire held-to-maturity securities for the quarter ending 2025-04-30 was -$4.00K, a 100.01% decline year-over-year.
- RAFAEL HOLDINGS, INC. payments to acquire held-to-maturity securities for the quarter ending 2025-01-31 was $1.17M, a 97.97% decline year-over-year.
- RAFAEL HOLDINGS, INC. payments to acquire held-to-maturity securities for the quarter ending 2024-10-31 was $15.73M, a 66.91% decline year-over-year.
- RAFAEL HOLDINGS, INC. payments to acquire held-to-maturity securities for fiscal 2025 was $16.99M, a 89.09% decline from fiscal 2024.
- RAFAEL HOLDINGS, INC. payments to acquire held-to-maturity securities for fiscal 2024 was $155.66M, a 23.99% decline from fiscal 2023.
- RAFAEL HOLDINGS, INC. payments to acquire held-to-maturity securities for fiscal 2023 was $204.80M.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2025-07-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $90.00K derived: sum of 2 quarters · filed 2026-06-11 | $1.26M derived: sum of 3 quarters · filed 2026-06-11 | $16.99M 10-K · filed 2025-10-29 |
| 2025-04-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11 | $1.17M derived: sum of 2 quarters · filed 2026-06-11 | $16.89M 10-Q · filed 2026-06-11 | $38.88M derived: sum of 4 quarters · filed 2026-06-11 |
| 2025-01-31 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16 | $16.90M 10-Q · filed 2026-03-16 | $38.88M derived: sum of 3 quarters · filed 2026-03-16 | $67.49M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-10-31 | $15.73M 10-Q · filed 2025-12-12 | $37.72M derived: sum of 2 quarters · filed 2025-12-12 | $66.32M derived: sum of 3 quarters · filed 2025-12-12 | $123.86M derived: sum of 4 quarters · filed 2025-12-12 |
| 2024-07-31 | $21.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $50.59M derived: sum of 2 quarters · filed 2025-10-29 | $108.13M derived: sum of 3 quarters · filed 2025-10-29 | $155.66M 10-K · filed 2025-10-29 |
| 2024-04-30 | $28.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | $86.14M derived: sum of 2 quarters · filed 2025-06-11 | $133.67M 10-Q · filed 2025-06-11 | $172.13M derived: sum of 4 quarters · filed 2025-06-11 |
| 2024-01-31 | $57.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14 | $105.06M 10-Q · filed 2025-03-14 | $143.52M derived: sum of 3 quarters · filed 2025-03-14 | |
| 2023-10-31 | $47.52M 10-Q · filed 2024-12-11 | $85.98M derived: sum of 2 quarters · filed 2024-12-20 | ||
| 2023-07-31 | $38.46M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $204.80M 10-K/A · filed 2024-12-20 | ||
| 2023-04-30 | $166.34M 10-Q · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |